Twenty-four patients had tumor samples collected at both time points that were adequate for IHC analysis, and 15 of these patients had paired samples adequate for RNA sequencing analysis Of the 24 patients, 10 were considered to be responders, based on the presence of a decline in the serum PSA by at least 50%, or a decrease in tumor volume by at least 30% on day 1 of cycle 4 of BAT. The gene discussed is KLK3; the disease is neoplasm.